Welcome to our dedicated page for Immix Biopharma SEC filings (Ticker: IMMX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Immix Biopharma, Inc. (IMMX) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, along with AI-powered summaries to help interpret key regulatory documents. Immix Biopharma is a Nasdaq-listed clinical-stage biopharmaceutical company developing cell therapies for relapsed/refractory AL amyloidosis and other serious diseases, and its filings offer detailed insight into governance, financing and risk disclosures that complement its clinical news.
Investors can review current reports on Form 8-K where Immix Biopharma describes material events such as private placements of common stock and non-transferable warrants, registered offerings of common stock and pre-funded warrants under a Form S-3 shelf registration statement, and changes to its board of directors. Filings also confirm that the company’s common stock trades on The Nasdaq Stock Market LLC under the symbol IMMX and document matters submitted to stockholders, including director elections and the ratification of its independent registered public accounting firm.
For longer-term analysis, users can access annual reports on Form 10-K and quarterly reports on Form 10-Q (when available via EDGAR) to study Immix Biopharma’s financial statements, risk factors, and detailed descriptions of its lead BCMA-targeted CAR-T program NXC-201 and the NEXICART-2 clinical trial. AI-generated highlights on Stock Titan help explain complex sections, point out important changes from prior periods, and summarize topics such as capital structure, use of proceeds from offerings, and auditor relationships.
In addition, this page surfaces registration statements, prospectus supplements and related consents that underpin Immix Biopharma’s capital-raising activities. Real-time updates from EDGAR combined with AI summaries make it easier to follow how financings, governance decisions and clinical strategy are reflected in the company’s official regulatory record.
Immix Biopharma, Inc. (IMMX) – Form 4 filed 06/23/2025
The filing discloses one transaction by Director and 10% owner Yekaterina (Katie) Chudnovsky dated 06/20/2025. She received a stock-option grant for 33,000 shares of common stock with an exercise price of $2.24 per share and an expiration date of 06/20/2035. The option vests in twelve equal monthly installments, contingent on continued board service. The option was acquired at no cost (transaction code “A”).
No non-derivative shares were bought or sold; the filing merely repeats her existing indirect ownership of 3,241,076 common shares held through GKCC, LLC, of which she is the sole member and manager. After the reported transaction, her total beneficial holdings stand at 3,241,076 shares (indirect) plus 33,000 derivative securities (direct).
Overall, the filing signals continued alignment between the director and shareholders through a sizeable existing stake and modest additional option incentives. The transaction does not materially alter the company’s share count or insider ownership structure.
Form 4 overview: Immix Biopharma, Inc. (ticker: IMMX) filed a Form 4 reporting an open-market purchase by Chief Financial Officer and Director Gabriel S. Morris on 18 June 2025.
- Transaction details: Mr. Morris bought 2,225 common shares at a volume-weighted average price of $2.279 per share (code “P”).
- Direct ownership after transaction: 288,059 common shares held in his own name (ownership code “D”).
- Indirect ownership: 270,844 shares held through Alwaysraise LLC and 24,141 shares held through Alwaysraise Ventures I LP (ownership code “I”). For both entities, Mr. Morris disclaims beneficial ownership except to the extent of his pecuniary interest.
- No derivative securities were reported in Table II.
- The filing was electronically signed by Mr. Morris on 20 June 2025.
The Form 4 reflects Mr. Morris’ latest equity position and provides investors with an updated view of insider holdings as of 18 June 2025.